On Oct. 15, J&J (JNJ) announced strong third-quarter results, beating estimates for both earnings and sales. The Innovative Medicine segment outperformed expectations. However, the MedTech segment underperformed due to continued headwinds in Asia-Pacific markets like China.Sales in the Innovative Medicine segment rose 4.9% year over year to $14.58 billion. Higher sales of key products such as Darzalex, Tremfya, Uptravi, Opsumit and Erleada drove the segment’s growth. New drugs like Carvykti, Tecvayli and Sp ...